Programme
ColpoCare
Single-visit colposcopy and treatment. You screen and refer. We treat. The patient comes back to you.
The problem we fix
Why the status quo does not work.
Screening finds abnormalities, but the path from an abnormal result to treatment is slow, multi-visit and often lost to follow-up. Nurses and GPs are not always sure when to refer, so women fall through the gap.
What changes for the patient
The pathway.
- The patient is seen in a single visit. Colposcopy and treatment, where needed, happen in the same sitting.
- Treatment is thermal ablation, LLETZ or biopsy, chosen on the findings.
- Results and a recall schedule go back to the referring clinician: a six-month test-of-cure, then annual follow-up for five years.
What changes for you
The clinician's experience.
- You stay the patient's doctor. You screen, you refer, and the patient returns to you with a care plan and recall dates.
- We handle the procedure, the authorisation (Discovery direct) and the follow-up loop.
- Trained nurses, GPs and medical officers can deliver see-and-treat colposcopy. We train and credential you for it.
- This is shared care. The follow-up, including the six-month test of cure, is delegated back to you for a fee.
When to refer
Refer a patient when you see any of these.
- An abnormal Pap smear or a positive HPV result.
- Known or suspected cervical intraepithelial neoplasia (CIN).
- A suspicious-looking cervix on examination.
- Post-coital, postmenopausal or heavy menstrual bleeding.
- Persistent or foul-smelling vaginal discharge.
- External vulval warts.
- Evaluation of a survivor of sexual assault.
Screening and referral, by result
What to do with each result.
Primary HPV DNA testing for all women from age 25, with self-sampling to widen reach. HPV-negative women rescreen in 10 years; women living with HIV rescreen every five years, for life. Network One Health does not use VIA or reflex cytology to triage: any high-risk HPV-positive result goes straight to colposcopy.
- HPV negative: Routine rescreen: in 10 years, or every five years for women living with HIV.
- Any high-risk HPV positive: Automatic colposcopy. We treat by findings: thermal ablation where there is no visible lesion, or LLETZ where a lesion is seen.
- Suspicious cervix or suspected invasive cancer: Do not take cytology. Take a punch biopsy and refer urgently to a higher level of care.
Special groups
- Pregnant women: screen before 20 weeks; defer treatment to six weeks postpartum unless invasive cancer is suspected, in which case refer urgently.
- Women living with HIV: start screening at 25 and repeat every five years, for life.
- Previously treated (LLETZ, thermal ablation or conisation): annual follow-up; refer to a higher level of care if screening stays positive.
Aligned to the 2026 National Cervical Cancer Elimination Framework and adapted to our colposcopy-first model: any high-risk HPV-positive result is referred directly for colposcopy.
Patient information: hpmanyonga.com/colpo-care
How you participate
No capital. No infrastructure to fund.
There is no capital to put in. We train and credential you for see-and-treat colposcopy, then handle the procedure logistics, the authorisation and the follow-up loop. The delegated follow-up work, including the six-month test of cure, is paid; we do not pay for referrals themselves. We agree the terms with you upfront.
What is expected of you
The standing asks.
- Active professional registration and indemnity, notified on onboarding.
- Completion of see-and-treat colposcopy training and credentialing.
- Records in the designated EMR, with the follow-up loop closed for every patient.
Why it is credible
Dr Manyonga pioneered nurse- and GP-initiated colposcopy training in South Africa, and the eight-centre Kiara Health training programme is extending it.
Refer a patient, or take part.
Send a patient to any of our active sites, or see the roles we are recruiting and express your interest.